Biomarkers predict benefit of targeted therapy in metastatic renal-cell cancer

[News]

In metastatic renal-cell cancer, the level of cytokines and angiogenic factors identify those patients with an aggressive disease course who derive the greatest benefit from treatment with the molecular-targeted therapy pazopanib, a retrospective analysis of clinical trials shows.Licensed from Medwire news with permission from Springer Healthcare Ltd. ©Springer Healthcare Ltd. All rights reserved. Neither of these parties endorse or recommend any commercial products, services, or equipment.



More... (http://www.news-medical.net/news/20120710/Biomarkers-predict-benefit-of-targeted-therapy-in-metastatic-renal-cell-cancer.aspx)